Faktor Stent yang Mempengaruhi Inflamasi Setelah Dilakukan IKP pada Pasien PJK Stabil
DOI:
https://doi.org/10.56260/sciena.v1i4.54Keywords:
Inflamasi, Intervensi perkutan koroner, Penyakit jantung koroner stabilAbstract
Prosedur intervensi koroner perkutan (IKP) merupakan prosedur revaskularisasi paling umum pada penyakit jantung koroner (PJK) stabil. Selain sebagai managemen PJK stabil, prosedur IKP juga dapat menyebabkan komplikasi. IKP mengakibatkan ruptur plak yang diinduksi mekanik, kerusakan endotel, dan barotrauma ke dinding pembuluh darah, sehingga terjadi inflamasi, yang pada akhirnya dikaitkan dengan peningkatan risiko KKM. Reaksi inflamasi akibat pemasangan stent dapat dipengaruhi oleh beberapa faktor, salah satunya faktor stent. Jika faktor-faktor ini tidak diatasi, maka akan terjadi peningkatan inflamasi setelah IKP yaitu aktivasi sel endotel, aktivasi platelet, infiltrasi leukosit, hiperplasia neointima, dan melibatkan banyak mediator.
References
. Roth GA, Huffman MD, Moran AE, Feigin V, Mensah GA, Naghavi M, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation. 2015; 132: 1667-1678.
. World Health Organization. The Top Ten Causes of Death. Diunduh dari http://www.who.int/mediacentre/factsheets/fs310/en/. 2022.
. RISKEDAS. Badan Pnelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar (RISKEDAS). L Nas. 2013; 1-384.
. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. ESC guidelines on the management of stable coronary artery disease. The task force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal. 2013;34:2949–3003
. Munk PS, Breland UM, Aukrust P, Skadberg O, Ueland T, Larsen AI. Inflammatory response to percutaneous coronary intervention in stable coronary artery disease. J Thromb Thrombolysis. 2011; 31:92–98.
. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014; 46: 517–592.
. Gomes WJ, Buffolo E. Coronary stenting and Inflammation: implications for further surgical and medical treatment. Ann Thorac Surg. 2006; 81: 1918 –1925.
. Schillinger M, Minar E. Restenosis after percutaneous angioplasty: the role of vascular inflammation. Vascular Health and Risk Management. 2005; 1: 73–78.
. Frederick G.P. Welt, Campbell Rogers. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22: 1769-1776.
. Schmidt T, Abbott JD. Coronary Stents: History, Design, and Construction. J. Clin. Med. 2018; 7: 126-134.
. Iqbal J, Gunn J, Serruys PW. Coronary stents: Historical development, current status and future directions. Br. Med. Bull. 2013; 106: 193–211.
. Watson T, Webster MW, Ormiston JA, Ruygrok PN, Stewart JT. Long and short of optimal stent design. Open Heart. 2017; 4: e000680.
. Butany J, Carmichael K, Leong SW, Collins MJ. Coronary artery stents: identification and evaluation. J Clin Pathol. 2005; 58: 795–804.
. Conti M, Auricchio F, Denis VL, Beule MD. Impact of carotid stent cell design on vessel scaffolding: a case study comparing experimental investigation and numerical simulations. Journal of Endovascular Therapy. 18(3):397-406.
. Lupi A, Schaffer A, Bongo AS. Should ultrathin strut drug eluting stents be considered the new benchmark for novel coronary stents approval? The complex interplay between stent strut thickness, polymeric carriers and antiproliferative drugs. Thorac Dis 2018;10(2):678-681
. Lee DH, Hernandez J. The newest generation of drug eluting stents and beyond. European Cardiology Review. 2018; 13(1): 54-59.
. Strohbach A, Busch R. Polymer for cardiovascular stent coatings. International Journal of Polymer Science. 2015: 1-12.
. Urban P, Meredith IT, Abizaid A, Pocock SJ, LEADERS FREE Investigators. Polymer-free drug-coated coronary stents in patientsat high bleeding risk.N Engl J Med. 2015;373:2038–2047.
. Baquet M, Jochheim D, Mehilli J. Polymer-free drug-eluting stents for coronary artery disease. J Interven Cardiol. 2018; 31: 330–337.
. Thakkar AS, Dave BA. Revolution of drug-eluting coronary stents: an analysis of market leaders. EMJ. 2016;1(4):114-125.
. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC,et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115:1051-1058.
. Monraats PS, Pires N, Agema W, Zwinderman AH, Schepers A, Maat M. Genetic Inflammatory Factors Predict Restenosis After Percutaneous Coronary Interventions. Circulation. 2005; 112: 2417-2425.
. Choi IJ, Koh YS, Lim S, Kim JJ, Chang M, Kang M. Impact of the stent length on long-term clinical outcomes following newer-generation drug-eluting stent implantation. Am J Cardiol. 2014;113(3):457-464.
. Stone GW, Parise H, Witzenbichler B, Kirtane A, Guagliumi G, Peruga JZ, et al. Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2010;56:1597-604.
. Popma JJ, Tiroch K, Almonacid A, Cohen S, Kandzaki DE, Leon MB. A qualitative and quantitative angiographic analysis of stent fracture late following sirolimus-eluting stent implantation. Am J Cardiol. 2009; 103: 923-929.
. Anggraini, D., Adelin, P. (2020). Risk Factors Of Cardiovascular Disease In Elderly In Guguak Kabupaten 50 Kota, West Sumatera, Indonesia. Human Care Journal, 5(1), 348-351. http://dx.doi.org/10.32883/hcj.v5i1.650
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Dian Puspita
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
